DCM
STML

Driehaus Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Driehaus Capital Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-94,273
Closed -$1.85M – 599
2013
Q4 		$1.85M Sell
94,273
-35,642
-27% -$951K 0.07% 330
2013
Q3 		$5.88M Buy
+129,915
New +$4.24M 0.23% 144

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Driehaus Capital Management's STML Position: Q1 2014 in Review

Driehaus Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q1 2014, closing a stake of 94,273 shares — an estimated $1.85M sold.

Driehaus Capital Management first reported a position in STML in Q3 2013 and held it in 2 quarters. The position peaked at $5.88M in Q3 2013. 61 funds tracked by Wall St. Rank hold STML as of Q1 2014.

  • Driehaus Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
  • Driehaus Capital Management sold 94,273 Stemline Therapeutics, Inc. shares in Q1 2014, an estimated $1.85M.
  • Driehaus Capital Management first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 2 quarters.
  • Driehaus Capital Management's Stemline Therapeutics, Inc. position peaked at $5.88M in Q3 2013.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2014.

Based on Driehaus Capital Management's 13F filing for Q1 2014, filed 15 May 2014.